EP0957916A1 - Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme - Google Patents

Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme

Info

Publication number
EP0957916A1
EP0957916A1 EP97932349A EP97932349A EP0957916A1 EP 0957916 A1 EP0957916 A1 EP 0957916A1 EP 97932349 A EP97932349 A EP 97932349A EP 97932349 A EP97932349 A EP 97932349A EP 0957916 A1 EP0957916 A1 EP 0957916A1
Authority
EP
European Patent Office
Prior art keywords
clidinium
pharmaceutical composition
recited
enantiomerically enriched
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97932349A
Other languages
German (de)
English (en)
Other versions
EP0957916A4 (fr
Inventor
Vincent L. Fabiano
John R. Mccullough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP0957916A1 publication Critical patent/EP0957916A1/fr
Publication of EP0957916A4 publication Critical patent/EP0957916A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Definitions

  • the present invention relates to methods for treating urinary incontinence, such as incontinence caused by bladder detrusor muscle instability, and to pharmaceutical compositions for such treatment.
  • Urinary incontinence is a prevalent problem that affects people of all ages and levels of physical health, both in healthcare settings and in the community at large.
  • urinary incontinence afflicts 15-30% of elderly people living at home, one-third of those living in acute-care settings, and at least one-half of those in long-term care institutions (R.M. Resnick, Lancet 246:94 (1995)).
  • Medically it predisposes persons to urinary tract infections, pressure ulcers, perineal rashes, and urosepsis.
  • urinary incontinence is associated with embarrassment, social stigmatization, depression, and with the risk of institutionalization (Herzo et al, Annu. Rev. Gerontol. Geriatr., 9:74 (1989)). Economically, the costs are great; in the United States alone, over $10 billion is spent per annum managing incontinence.
  • Treatments for incontinence include drugs with bladder relaxant properties, i.e., which help to control bladder detrusor muscle overactivity.
  • Such drugs are effective in 80 to 85% of patients with uninhibited bladder contractions, with anticholinergic medications representing the mainstay of this type of treatment.
  • anticholinergics such as propantheline bromide
  • combination smooth muscle relaxant/anticholinergics such as racemic oxybutynin and dicyclomine
  • racemic oxybutynin is considered the drug of first choice in patients with bladder detrusor muscle hyperactivity when pharmacological therapy is indicated (cf. Yarllur et al, Drugs Aging, 6:243 (1995)).
  • Another anticholinergic drug, clidinium, 3-hydroxy- 1 -methyl quinuclidinyl benzilate is described in the literature for use as adjunctive therapy in peptic ulcer disease, and has been used in muscarinic receptor labeling studies (Brunner et al, Brit. J.
  • the present invention provides methods and compositions for treatment of urinary incontinence, including, e.g., bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostectomy incontinence, with (R)-clidinium.
  • the methods of the present invention provide for treatment of incontinence with fewer adverse effects than occur upon administration of racemic clidinium.
  • One aspect of the present invention relates to methods for treating urinary incontinence by administration to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof.
  • the enantiomerically enriched (R)- clidinium, or a pharmaceutically acceptable salt thereof is substantially free of (S)-clidinium.
  • the present invention also relates to methods for treating bladder detrusor muscle instability comprising administration to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof.
  • the enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof is substantially free of (S)-clidinium.
  • Another aspect of the present invention relates to pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (R)- clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions of the present invention comprise (R)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of (S)-clidinium.
  • the present invention also provides for formulating the pharmaceutical compositions of the present invention, comprising enantiomerically enriched (R)- clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in pharmaceutical unit dosage forms, including, e.g., tablets and soft elastic gelatin capsules.
  • kits for treating urinary incontinence such as bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostectomy incontinence
  • said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering the same while reducing or eliminating anticholinergic adverse effects associated with administration of racemic clidinium, or other incontinence drugs with anticholinergic action.
  • the enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof is substantially free of (S)-clidinium.
  • urinary incontinence can be caused by uncontrolled or unstable bladder contractions, particularly of the bladder detrusor muscle which serves to force fluids out of the bladder.
  • the major proportion of the neurohumeral stimulus for physiologic bladder contraction is acetylcholine-induced stimulation of postganglionic muscarinic receptor sites on bladder smooth muscle.
  • most pharmacologic treatments for incontinence associated with uninhibited bladder contractions include medications with anticholinergic and smooth muscle relaxant properties.
  • many of the anticholinergic agents which have been used for the treatment of incontinence often have adverse effects associated with their anticholinergic actions, which result in at least periodic discontinuation of use in a significant portion of the treated population.
  • the present invention relates to compositions and methods for the treatment of bladder instability in mammals, such as humans. More specifically, this invention provides enantiomerically enriched preparations of (R)-clidinium and methods for their use in the treatment of urinary incontinence, including, e.g., bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostectomy incontinence.
  • One feature of the subject non-racemic preparations of (R)-clidinium derives from the enantiomer's pharmacological advantage over the racemate in terms of its principal therapeutic and side effect profile.
  • Certain deleterious local and/or systemic adverse effects of the racemic mixture e.g., drowsiness, xerostomia, mydriasis, constipation, cycloplegia, cardiac arrhythmia and/or epistaxis may be reduced through treatment with enantiomerically enriched (R)-clidinium.
  • R enantiomerically enriched
  • the present invention provides a method for treating urinary incontinence using (R)-clidinium, which results in a reduction of the adverse effects associated with administration of racemic clidinium.
  • the method comprises administering to a patient in need thereof a pharmaceutically effective amount of (R)- clidinium, or a pharmaceutically acceptable salt thereof, substantially free of (S)- clidinium.
  • the methods of the present invention are used to treat urinary incontinence due to bladder detrusor muscle instability. Such instability may result in, for example, stress incontinence or urge incontinence, or combination thereof, and/or enuresis.
  • the present invention provides pharmaceutical compositions which comprise an enantiomerically enriched preparation of (R)-clidinium, or a pharmaceutically acceptable salt thereof, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
  • the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for oral administration, parenteral administration, or topical application.
  • certain terms employed in the specification, examples, and appended claims are collected here.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • S and R the terms “S” and “R” configuration are as defined by the IUPAC 1974 Recommendations for Section E., Fundamental Stereochemistry, Pure Appl. Chem., 45.: 13-30 (1976).
  • racemate and enantiomer will be used in their normal context to describe the stereochemistry of clidinium preparations.
  • enantiomerically enriched and “non-racemic”, as used interchangeably herein with reference to preparations of clidinium refer to clidinium compositions in which the (R)-clidinium enantiomer is enriched, compared to a control mixture of (R)-clidinium and (S)-clidinium enantiomers. Unless otherwise specified, such terms refer to clidinium compositions in which the ratio of (R)-clidinium to (S)-clidinium enantiomers is greater than 1 : 1 by weight.
  • an enantiomerically enriched preparation of (R)-clidinium means a preparation of clidinium having greater than 50% by weight of the (R)-clidinium enantiomer relative to the (S)-clidinium enantiomer, more preferably at least 75% by weight, and even more preferably at least 80% by weight.
  • the enrichment can be much greater than 80% by weight, providing a "substantially enantiomerically enriched” or a “substantially non-racemic" preparation, which refers to preparations of clidinium which have at least 85% by weight of the (R)- clidinium enantiomer relative to the (S)-clidinium enantiomer, more preferably at least 90% by weight, and even more preferably at least 95% by weight.
  • substantially free of (S)-clidinium will be understood to have similar purity ranges., i.e., at least 85% by weight of the (R)-clidinium enantiomer relative to the (S)-clidinium enantiomer, more preferably at least 90% by weight, and even more preferably at least 95% by weight.
  • adverse effects refers to effects associated with administration of racemic clidinium, which are not part of the desired therapeutic effect of the drug.
  • such adverse effects include, for illustrative purposes, drowsiness, epistaxis, xerostomia, mydriasis, cycloplegia, unstable cardiovascular status such as arrhythmia (e.g., tachycardia or palpitations), increased ocular pressure, nausea, constipation, decreased sweating, impotence, and/or dermal manifestations such as urticaria.
  • arrhythmia e.g., tachycardia or palpitations
  • increased ocular pressure nausea, constipation, decreased sweating, impotence, and/or dermal manifestations such as urticaria.
  • Epistaxis refers to nosebleeds, e.g., hemorrhage from the nose. Epistaxis is a side effect of anticholinergics in children.
  • xerostomia refers to dryness of the mouth due to lack of normal secretion.
  • mydriasis refers to dilation of the pupil, and often results in blurred vision.
  • cycloplegia refers to paralysis of the ciliary muscle; paralysis of accommodation.
  • enuresis refers to the involuntary discharge of urine
  • nocturnal enuresis refers to involuntary discharge of urine during sleep at night.
  • enantiomers can be accomplished in several ways known in the art. For example, a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (see, e.g., "Chiral Liquid Chromatography", W.J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereometric salts and fractional crystallization can be used to separate enantiomers.
  • the diastereometric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like.
  • diastereometric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid.
  • the active enantiomer of clidinium can be synthesized by stereospecific synthesis to produce only the desired optical isomer using methodology well known to those skilled in the art. Chiral synthesis can result in products of high enantiomeric purity. However, in some cases, the enantiomeric purity of the product is not sufficiently high.
  • the separation methods described above can be used to further enhance the enantiomeric purity of clidinium obtained by chiral synthesis.
  • the optical purity of the (R)-clidinium can be determined by methods known in the art. For example, a sample of the clidinium can be analyzed by high performance liquid chromatography on a chiral chromatographic column. Another method of determining optical purity involves making a chiral ester, such as a Mosher ester, of a clidinium sample, and analyzing the NMR spectrum for the presence of the undesired enantiomer.
  • a chiral ester such as a Mosher ester
  • (R)-clidinium is substantially free of (S)-clidinium.
  • “Substantially free” as used herein means that at least 85% by weight of the total clidinium present is the (R)-clidinium enantiomer; more preferably at least 90% by weight, and still more preferably at least 95% by weight is the (R)-clidinium enantiomer. In a more preferred embodiment, at least 99 % by weight of the total clidinium present is the (R)-clidinium enantiomer.
  • (R)-clidinium can be used to treat urinary incontinence, including, e.g., bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, and post-prostectomy incontinence, by administration to a patient according to any suitable route of administration.
  • a preferred method of administration is oral administration.
  • Another preferred route of administration is intravenous administration.
  • a particularly preferred route of administration is intravesical delivery, i.e., administration directly to the bladder, e.g., by injection or infusion.
  • (R)-clidinium is preferably administered as a pharmaceutical formulation (composition).
  • pharmaceutical formulation composition
  • pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • (R)-clidinium contains a quaternary amino functional group, and thus is capable of forming pharmaceutically acceptable salts.
  • “pharmaceutically acceptable salts” in this respect, refers to the relatively non-toxic, inorganic and organic salts of (R)-cIidinium. These salts can be prepared in situ during the final isolation and purification of the (R)-clidinium.
  • Representative salts include the bromide, chloride, hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benxoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate salts and the like.
  • Berge et al "Pharmaceutical Salts", J. P harm. Sci., ⁇ &: ⁇ -]9 (1977).
  • Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which is combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, and the particular mode of administration.
  • the amount of active ingredient which may be combined with a carrier material to produce a single dosage form preferably will be that amount of (R)-clidinium which produces a therapeutic effect.
  • the amount of the active ingredient will range from about 1 % to about 99 % of the total formulation, preferably from about 5 % to about 70 %, and most preferably from about 10 % to about 30 %.
  • Methods of preparing these formulations or compositions include the step of bringing into association (R)-clidinium with a pharmaceutically acceptable carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association (R)-clidinium with liquid carriers, or finely divided solid carriers, or both, and any optional accessory ingredients, and then, if necessary, shaping the product.
  • pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the (R)-clidinium from one organ, or portion of the body, to another organ or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically acceptable carriers include: ( 1 ) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydro
  • Formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as a gelatin and glycerin, or sucrose and acacia), or as soft elastic gelatin capsules, and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • (R)-clidinium may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or may also be mixed with one or more of any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting
  • pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate
  • fillers or extenders such as starches, lactose, suc
  • the pharmaceutical compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. Release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions of the present invention.
  • antioxidants examples include: (1 ) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), and/or surface-active or dispersing agents.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered (R)-clidinium moistened with an inert, liquid diluent.
  • the pharmaceutical compositions of the present invention may also be formulated in a soft elastic gelatin capsule unit dosage form by using conventional methods, well- known in the art (see, e.g., Ebert, Pharm.
  • Soft elastic gelatin capsules have a soft, globular, gelatin shell somewhat thicker than that of hard gelatin capsules, wherein a gelatin is plasticized by the addition of glycerin, sorbitol, or a similar polyol.
  • the hardness of the capsule shell may be changed by varying the type of gelatin and the amounts of plasticizer and water.
  • the soft gelatin shells may contain a preservative to prevent the growth of fungi, such as methyl- and propylparabens and sorbic acid.
  • the active ingredient may be dissolved or suspended in a liquid vehicle or carrier, such as vegetable or mineral oils, glycols such as polyethylene glycol and propylene glycol, triglycerides, surfactants such as polysorbates, or a combination thereof.
  • the tablets, and other dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
  • compositions of the present invention may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may also be administered by controlled release means and delivery devices such as those in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,796; and PCT published application WO92/20377.
  • compositions of the present invention may also optionally contain opacifying agents and may be formulated such that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of (R)-clidinium include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol,
  • the oral compositions of the present invention can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active (R)-clidinium, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Formulations of the pharmaceutical compositions of the present invention for rectal and vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate.
  • suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate.
  • Such formulations of the present invention are solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active (R)-clidinium.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of (R)-clidinium include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • Formulations of the present invention in the form of ointments, pastes, creams and gels may contain, in addition to (R)-clidinium, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and/or zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and/or zinc oxide, or mixtures thereof.
  • Powders and sprays may contain, in addition to (R)-clidinium, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays may additionally contain customary propellants, such as, for example, chlorofluorohydrocarbons, volatile unsubstituted hydrocarbons, hydrocarbon ethers and compressed gases.
  • Transdermal patches have the added advantage of providing controlled delivery of the active (R)-clidinium of the present invention to the body.
  • dosage forms may be made by dissolving or dispersing the (R)-clidinium in the proper medium.
  • Absorption enhancers may also be used to increase the flux of the (R)-clidinium across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the (R)-clidinium in a polymer matrix or gel.
  • the pharmaceutical compositions of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Where necessary, the pharmaceutical compositions of the present invention are sterile or can be sterilized before administration to a patient.
  • the enantiomerically enriched clidinium compositions of the present invention are provided in tablet or capsule form with, as inactive ingredients, dibasic calcium phosphate, lactose, magnesium stearate, providone and sodium starch glycolate.
  • the capsules or tablets are preferably formulated with from about 0.25 mg to about 250 mg of (R)-cIidinium, more preferably with from about 0.50 mg to about 100 mg of (R)-clidinium, and even more preferably with from about 1 mg to about 50 mg of(R)-clidinium.
  • the enantiomerically enriched (R)-clidinium preparations of the present invention are provided in soft elastic gelatin capsule form.
  • the soft elastic gelatin capsules are preferably formulated with from about 0.25 mg to about 250 mg of (R)-clidinium, more preferably with from about 0.50 mg to about 100 mg of (R)-clidinium, and even more preferably with from about 1 mg to about 50 mg of (R)- clidinium.
  • Actual dosage levels of (R)-clidinium in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level and frequency of administration will depend upon a variety of factors including the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the (R)-clidinium, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • the dosage regimen is likely to vary with pregnant women, nursing mothers and children relative to healthy adults.
  • a physician having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician could start doses of the compound employed in the pharmaceutical composition of the present invention at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of (R)-clidinium will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, the total daily dose of (R)- clidinium for the conditions described herein may be from about 0.25 mg to about 500 mg, more preferably from about 0.50 mg to about 250 mg, and more preferably from about 1 mg to about 100 mg.
  • the effective daily dose of the active (R)-clidinium may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • kits for treating urinary incontinence including, e.g., bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostectomy incontinence
  • said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering enantiomerically enriched (R)-clidinium for the treatment of urinary incontinence while reducing or eliminating anticholinergic adverse effects associated with racemic clidinium or other incontinence drugs with anticholinergic action.
  • (R)-clidinium may be established by the following studies of antimuscarinic, spasmolytic, and calcium entry blocking effects in models of receptor binding and bladder function.
  • the assays are rapidly filtered under vacuum through GF B glass fiber filters (available, e.g., from Whatman) and washed with an ice-cold buffer using a Brandel Cell Harvester. Bound radioactivity is determined with a liquid scintillation counter (e.g., LS6000, Beckman) using a liquid scintillation cocktail (e.g., Formula 99, DuPont NEN).
  • GF B glass fiber filters available, e.g., from Whatman
  • Bound radioactivity is determined with a liquid scintillation counter (e.g., LS6000, Beckman) using a liquid scintillation cocktail (e.g., Formula 99, DuPont NEN).
  • the compounds are tested on each receptor at 10 concentrations in duplicate to obtain competition curves.
  • the reference compound for the receptor under investigation is simultaneously tested at 8 concentrations in duplicate to obtain a competition curve in order to validate this experiment.
  • the specific radioligand binding of each receptor is defined as the difference between total binding and nonspecific binding determined in the presence of an excess of unlabelled ligand.
  • IC 50 values concentration required to inhibit 50% of specific binding are determined by non linear regression analysis of the competition curves. These parameters are obtained by curve fitting using SigmaplotTM software. Binding to Calcium Channels
  • Binding assays are performed using the methods set forth in Table 2.
  • the assays are rapidly filtered under vacuum through GF B or GF/C glass fiber filters (available, e.g., from Whatman) and washed with an ice-cold buffer using a Brandel Cell Harvester. Bound radio-activity is determined with a liquid scintillation counter (e.g., LS 6000, Beckman) using a liquid scintillation cocktail (e.g., Formula 989, DuPont NEN).
  • GF B or GF/C glass fiber filters available, e.g., from Whatman
  • Bound radio-activity is determined with a liquid scintillation counter (e.g., LS 6000, Beckman) using a liquid scintillation cocktail (e.g., Formula 989, DuPont NEN).
  • the compounds are tested in duplicate on each receptor at a concentration of 10 " 5 M.
  • the reference compound for the receptor under investigation is simultaneously tested at 8 concentrations in duplicate to obtain a competition curve in order to validate this experiment.
  • the specific radioligand binding of each receptor is defined as the difference between total binding and nonspecific binding determined in the presence of an excess of unlabelled ligand. Mean values are expressed as a percentage of inhibition of specific binding. IC 50 values (concentration required to inhibit 50% of specific binding) are determined by non linear regression analysis of their competition curves. These parameters are obtained by curve fitting using SigmaplotTM software. Functional Characterization of Antimuscarinic/Antispasmodic Activity
  • (R)-clidinium are studied in an in vitro model of bladder function.
  • isolated strips of guinea pig bladder smooth muscle are mounted in a tissue bath and contracted either with the muscarinic agonist carbachol or with increasing concentrations of external potassium.
  • the tissues are suspended in an oxygenated buffer of the following composition, in mM: NaCl, 133; KCI, 4.7; CaCI 2 , 2.5; MgSO Register, 0.6; NaH 2 P0 4 , 1.3; NaHC0 3 , 16.3; and glucose, 7.7.
  • the tissues are maintained at 37.5° C. Isometric contractions of the tissues are recorded by using appropriate transducers and an ink-writing polygraph. A resting tension of 0.5 grams is maintained on each tissue at all times.
  • the vehicle controls are used when, because of poor solubility, stock solutions of the test substances are prepared in a vehicle, e.g., ethanol. Finally, the responses to increasing concentrations of carbachol followed by exposure to 137.7 mM KCI are recorded a second time.
  • Arunlakshana and Schild (1959) are used in modified form to estimate the pA2 and slope of the Schild regression.
  • the concentrations of agonist producing a half-maximal response (the EC 50 ) is estimated for each strip from the second set of concentration-effect data.
  • the EC 50 is obtained from linear regression lines fit to the logarithm of the concentration of drug and the responses bracketing the half maximum level of response.
  • a "concentration ratio" (CR) is calculated as the ratio of the EC 50 of the treated tissue divided by the EC ⁇ 0 of the untreated tissue.
  • logarithm of this ratio minus one i.e., log (CR-1)] is plotted against the logarithm of the concentration of antagonist to which the strip had been exposed to produce "Schild plots".
  • a regression analysis relating log(CR-l) to the logarithm of the concentration of the antagonist is employed to estimate the pA2 and the slope of the regression line.
  • experiments are grouped by test substance and the mean + S.E. of the pA2 and slope are calculated.
  • the 95% confidence limits (CL) for the slope are estimated from its S.E. using standard methods.
  • a pKD is calculated as (concentration of antagonist)/(CR-l) and the negative logarithm of the KD is then pooled with the pA2 values to yield an expanded set of pA2 values.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a pour objet un procédé pour traiter l'incontinence urinaire, telle l'incontinence résultant d'une instabilité du muscle vésical, utilisant du (R)-clidinium enrichi par énantiomorphisme. Le procédé comprend l'administration d'une quantité thérapeutiquement efficace de (R)-clidinium enrichi par énantiomorphisme, ou d'un sel de celui-ci acceptable selon des critères pharmaceutiques, pratiquement dépourvu de l'énantiomère (S)-clinidium. Ladite invention se réfère également à des compositions pharmaceutiques pour traiter l'incontinence urinaire, comportant du (R)-clinidium enrichi par énantiomorphisme, ou un sel de celui-ci acceptable selon des critères pharmaceutiques, et un excipient acceptable.
EP97932349A 1996-07-01 1997-06-27 Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme Withdrawn EP0957916A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2073096P 1996-07-01 1996-07-01
US20730P 1996-07-01
PCT/US1997/011258 WO1998000138A1 (fr) 1996-07-01 1997-06-27 Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme

Publications (2)

Publication Number Publication Date
EP0957916A1 true EP0957916A1 (fr) 1999-11-24
EP0957916A4 EP0957916A4 (fr) 2000-02-23

Family

ID=21800231

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97932349A Withdrawn EP0957916A4 (fr) 1996-07-01 1997-06-27 Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme

Country Status (2)

Country Link
EP (1) EP0957916A4 (fr)
WO (1) WO1998000138A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
CA2513188A1 (fr) 2003-01-16 2004-08-05 University Of Rochester Composes antimuscariniques quaternaires destines au traitement de maladies vesicales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAURI D.: "ÄIncontinence of urine: Possibilities for pharmacotherapyÜ." MEDIZINISCHE MONATSSCHRIFT FUR PHARMAZEUTEN, (1984) 7/8 (233-239). CODEN: MMPHDB, XP000863460 *
KOPPENHOEFER B. ET AL: "Separation of enantiomers of drugs by capillary electrophoresis I..gamma.-Cyclodextrin as chiral solvating agent." JOURNAL OF CHROMATOGRAPHY A, (1995) 717/1-2 (181-190). , XP000605057 *
KOPPENHOEFER, BERNHARD ET AL: "Separation of enantiomers of drugs by capillary electrophoresis Part 4: hydroxypropyl-gamma-cyclodextrin as chiral solvating agent" ELECTROPHORESIS (1997), 18(6), 924-930 , XP000863400 *
LIN B C (REPRINT) ET AL: "SEPARATION OF DRUG ENANTIOMERS BY CAPILLARY ELECTROPHORESIS ALPHA-CYCLODEXTRIN AS CHIRAL SOLVATING AGENT" CHROMATOGRAPHIA, (JAN 1996) VOL. 42, NO. 1-2, PP. 106-110. ISSN: 0009-5893., vol. 42, no. 1/2, 1996, pages 106-110, XP000863359 DALIAN INST CHEM PHYS, ZHONG SHAN RD 161, DALIAN 116012, PEOPLES R CHINA (Reprint);CHINA PHARMACEUT UNIV, NANJING 250009, PEOPLES R CHINA; UNIV TUBINGEN, INST ORGAN CHEM, D-72076 TUBINGEN, GERMANY *
LIN, BINGCHENG ET AL: "Investigation of 123 chiral drugs by cyclodextrin-modified capillary electrophoresis" LC-GC (1997), 15(1), 40, 44-46 , XP000863469 *
See also references of WO9800138A1 *
YURDAKOK M ET AL: "Treatment of enuresis: a study with imipramine, amitriptyline, chlordiazepoxide- clidinium and piracetam." TURKISH JOURNAL OF PEDIATRICS, (1986 JUL-SEP) 28 (3) 171-5. , XP000863478 *

Also Published As

Publication number Publication date
EP0957916A4 (fr) 2000-02-23
WO1998000138A1 (fr) 1998-01-08

Similar Documents

Publication Publication Date Title
US6204285B1 (en) Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
US6063808A (en) Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
US5736577A (en) Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
KR100390271B1 (ko) (s)-옥시부티닌과(s)-데스에틸옥시부티닌을이용한요실금치료
US5939426A (en) Methods for treating urinary incontinence using descarboethoxyloratadine
EP0909172A1 (fr) PROCEDES ET COMPOSITIONS POUR TRAITER L'INCONTINENCE URINAIRE AVEC DU (R,s)-GLYCOPYRROLATE ENRICHI EN ENANTIOMERES
WO1998000109A1 (fr) Procedes et compositions de traitement de l'incontinence urinaire a l'aide de (s,r)-glycopyrrolate enrichi en enantiomeres
US6063792A (en) Methods and compositions for treating urinary incontinence using enantiomerically enriched (S)-trihexyphenidyl
US6110972A (en) Methods and compositions for treating urinary incontinence using enantiomerically enriched (S)-tridihexethyl
US6207681B1 (en) Methods and compositions for treating urinary incontinence using enantiomerically enriched (R)-trihexyphenidyl
US6130242A (en) S-procyclidine for treating urinary incontinence
WO1998000138A1 (fr) Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme
EP0938313A1 (fr) Procedes et compositions pour traiter l'incontinence urinaire avec du (s)-clidinium enrichi par enantiomorphisme
EP0933992A1 (fr) Procedes et compositions de traitement de l'incontinence urinaire par (r)-tridihexethyle enrichi en enantiomere
AU2017999A (en) (r)-procyclidine for treating urinary incontinence
KR20000022194A (ko) (s)-옥시부티닌과 (s)-데스에틸옥시부티닌을 이용한 요실금치료

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000111

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011121